Loading...
XNAS
CHRN
Market cap56mUSD
Jun 18, Last price  
23.33USD
1D
13.20%
1Q
121.35%
Jan 2017
-97.39%
IPO
-99.37%
Name

Ekso Bionics Holdings Inc

Chart & Performance

D1W1MN
XNAS:CHRN chart
P/E
P/S
4.42
EPS
Div Yield, %
Shrs. gr., 5y
38.41%
Rev. gr., 5y
7.58%
Revenues
13m
-28.60%
2,706,0003,302,0003,302,0005,327,0008,661,00014,221,0007,353,00011,332,00013,917,0008,882,00011,246,00012,912,00018,279,00017,925,00012,799,000
Net income
-12m
L+3.22%
-15,042,000-12,292-12,292-33,769,000-19,590,000-23,470,000-29,122,000-26,992,000-12,132,000-15,825,000-9,764,000-15,080,000-15,198,000-11,330,000-11,695,000
CFO
-12m
L+19.86%
-11,992-11,992-15,007,000-18,269,000-24,997,000-31,226,000-22,165,000-15,772,000-8,755,000-11,156,000-14,688,000-12,054,000-9,846,000-11,801,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Ekso Bionics Holdings, Inc. is a global innovator in exoskeleton technology, specializing in the creation, production, sale, and leasing of these advanced devices across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. The company's operations are divided into two distinct segments: EksoHealth and EksoWorks. The EksoHealth division concentrates on engineering, manufacturing, and marketing exoskeletons designed for medical applications. Conversely, the EksoWorks segment develops and commercializes exoskeleton solutions intended for able-bodied individuals, empowering them to perform demanding, repetitive physical tasks for extended durations. Its product portfolio includes EksoNR, a sophisticated wearable bionic suit and rehabilitation tool. This device supports physical therapists and physicians in treating patients recovering from conditions such as acquired brain injury, stroke, and spinal cord injury. Additionally, the EksoUE is an assistive wearable device for the upper extremities, designed to lessen the gravitational load on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. also maintains a licensing agreement with Lockheed Martin Corporation. Founded in 2005, the company maintains its corporate headquarters in Richmond, California.
IPO date
Apr 10, 2013
Employees
72
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT